Pluri (NASDAQ:PLUR) and Curis (NASDAQ:CRIS) Critical Survey

Curis (NASDAQ:CRIS) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Insider and Institutional Ownership

30.0% of Curis shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 5.8% of Curis shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Curis has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Valuation & Earnings

This table compares Curis and Pluri”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$4.31 million	0.19	-$29.72 million	($14.22)	-0.03
Pluri	$1.02 million	14.77	-$30.90 million	($2.45)	-0.49

Curis has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Curis and Pluri, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1	1	1	0	2.00
Pluri	1	0	0	0	1.00

Curis currently has a consensus price target of $43.00, suggesting a potential upside of 10,583.23%. Given Curis’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Curis is more favorable than Pluri.

Profitability

This table compares Curis and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curis	N/A	N/A	N/A
Pluri	N/A	N/A	N/A

Summary

Curis beats Pluri on 8 of the 11 factors compared between the two stocks.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.